Collaborative Efforts Leading to Advances That Will Contribute to Health Care Reform

SUNNYVALE, CA — Arrayit Corporation (OTC.BB:ARYC – News) is pleased to join the federal government in their efforts to help control health care costs through early diagnosis of diseases.

For more than 150 years, traditional medicine has relied on a ‘standards of care’ model, which utilizes large cohorts of individuals as the data set and essentially treats every person in an identical manner. While this medical model provides a good paradigm for standard health care practices, it is woefully deficient in that it fails to include genetic and epigenetic differences between people as well as the interplay between our genes and environmental factors including medication, diet and other lifestyle considerations. In a major paradigm shift, personalized medicine is gaining rapid popularity in that it endeavors to provide customized health care to individuals inclusive of genetics, epigenetics and the environment, leading to early stage diagnosis of diseases that have exacted a heavy cost in quality and length of life and dollars spent in late stage treatment.

Personalized medicine is a vastly superior advance in health care if it can be delivered at a rate equivalent to or less than the current standards of care model. As a next generation health care company, Arrayit Corporation is capable of delivering personalized medical information to the public at a fraction of current costs, owing to the company’s unique ability to miniaturize, automate and massively parallelize genomic and proteomic tests. In simple terms, these molecular diagnostic tests, requiring only a blood sample, will be more accurate and less personally invasive than many traditional cancer screening methods. Arrayit’s patented microarray manufacturing technology and Variation Identification Platform (VIP) procedures, deployed in clinical laboratories and reference centers, are capable of testing entire population groups. Arrayit personalized medical tests for pre-symptomatic ovarian cancer detection, H1N1 screening, and Parkinson’s Disease diagnostics represent only a few of the collaborative milestones soon to be announced.

About Arrayit Corporation

Arrayit Corporation, headquartered in Sunnyvale, California, leads and empowers the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure. It now offers over 650 products to a customer base, including most every major university, pharmaceutical and biotech company, major agricultural and chemical company, government agency, national research foundation and many private sector enterprises. Please visit www.arrayit.com for more information.

Safe Harbor Statement

Except for historical information contained herein, statements made in this release that constitute forward-looking statements are based on currently available information, involve certain risks and uncertainties and the Company assumes no responsibility to update any such forward-looking statement. The following factors, among others, may cause actual results to differ materially from the results suggested in the forward-looking statements. Risks that may result from changes in the Company’s business operations; our ability to keep pace with technological advances; significant competition in the biomedical business; our relationships with key suppliers and customers; quality and consumer acceptance of newly introduced products; market volatility; non-availability of product; excess inventory; price and product competition; new product introductions, the outcome of our legal disputes; the possibility that the review of our prior filings by the SEC may result in changes to our financial statements; and the possibility that stockholders or regulatory authorities may initiate proceedings against Arrayit and/or our officers and directors as a result of any restatements. Risk factors associated with our business, including some of the facts set forth herein, are detailed in the Company’s Form 10-K/A for the fiscal year ended December 31, 2008 and Form 10-Q/A for the fiscal first quarter ended March 31, 2009 and Form 10-Q/A for the fiscal third quarter ended September 30, 2008.